Evidence map›Paper›PMID 39665521›Full record

ArticleESC heart failure2025

Progression and prognostic significance of electrocardiographic findings in patients with cardiac amyloidosis.

Alessia Argirò, Mattia Zampieri, Carlotta Mazzoni, Carlo Fumagalli, Michela Baccini, Alessandra Mattei, Alberto Cipriani, Laura De Michieli, Aldostefano Porcari, Gianfranco Sinagra and 11 more

Abstract readMulticenter Study
In one paragraph

Article in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Alessia ArgiròTuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy.ORCID https://orcid.org/0000-0002-6394-9948
Mattia ZampieriTuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy.
Carlotta MazzoniTuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy.
Carlo FumagalliTuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy.
Michela BacciniDepartment of Statistics, Computer Science, Applications (DISIA), University of Florence, Florence, Italy.
Alessandra MatteiDepartment of Statistics, Computer Science, Applications (DISIA), University of Florence, Florence, Italy.
Alberto CiprianiDepartment of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Laura De MichieliDepartment of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Aldostefano PorcariCenter for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy.
Gianfranco SinagraCenter for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy.
Marco MerloCenter for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy.
Giacomo TiniDepartment of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.
Beatrice MusumeciDepartment of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.
Domitilla RussoDepartment of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.
Pier Filippo VianelloCardiovascular Unit, Department of Internal Medicine, University of Genova, Ospedale Policlinico San Martino IRCCS, Genoa, Italy.
Marco CanepaCardiovascular Unit, Department of Internal Medicine, University of Genova, Ospedale Policlinico San Martino IRCCS, Genoa, Italy.
Roberto LicordariDepartment of Cardiology, University of Messina, Messina, Italy.
Gianluca di BellaDepartment of Cardiology, University of Messina, Messina, Italy.
Claudio RapezziCardiothoracic Department, University of Ferrara, Ferrara, Italy.
Federico PerfettoTuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy.
Francesco CappelliTuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThis study aimed to evaluate the change of the main electrocardiographic (ECG) characteristics and their prognostic role across the main subtypes of cardiac amyloidosis [light-chain amyloidosis (AL) and hereditary (ATTRv) and wild-type transthyretin amyloidosis (ATTRwt)]. METHODS AND

resultsThis multicentre, retrospective study was performed in six referral centres for cardiac amyloidosis. Clinical and ECG data were collected at the first and last evaluations. Three hundred fifty-six patients were included (AL, n = 105; ATTRv, n = 50; ATTRwt, n = 201). The median age was 76 (67-81) years, and 271 (74%) were men. At baseline, patients with ATTRwt showed a higher prevalence of conduction abnormalities compared with those with AL [first-degree atrioventricular block, n = 51 (40%) vs. n = 13 (34%), P < 0.01; left bundle branch block, n = 23 (11%) vs. n = 2 (2%), P < 0.01], and patients with AL more often had low QRS voltage [n = 58 (55%); in ATTRv, n = 17 (34%); in ATTRwt, n = 67 (33%), P value < 0.01] and T wave inversion compared with those with ATTR [n = 39 (37%); in ATTRv, n = 9 (18%); in ATTRwt, n = 37 (18%)]. After a median follow-up of 15 (8-26) months, the adjusted differences in mean PR, QRS interval, total, peripheral, and precordial QRS scores were similar across subtypes of amyloidosis (P value for linear regression > 0.05). The adjusted odds ratios for the development of right bundle branch block were higher in AL compared with ATTRwt [odds ratio 4.7 (95% confidence interval 1.5-15), P < 0.05]. QRS duration at baseline remained independently associated with patient survival in the overall population even after adjustment for relevant clinical variables [hazard ratio 1.78 (95% confidence interval 1.13-2.8), P < 0.01].

conclusionsThe progression of the ECG abnormalities seems similar across amyloidosis subtypes. QRS duration could be a marker of more advanced disease.

Indexed as

AmyloidosisCardiomyopathiesElectrocardiographyImmunoglobulin Light-chain AmyloidosisAgedAged, 80 and overAmyloid Neuropathies, FamilialDisease ProgressionFemaleFollow-Up StudiesHumansMalePrognosisRetrospective StudiesCardiac amyloidosisECGLight‐chain amyloidosisTransthyretin amyloidosis

Identifiers

PMID39665521
PMCPMC11911618

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.